Zymeworks BC

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Zymeworks BC sits in the upper quartile of US sponsors by registered trial count (#2,913 of 15,742 sponsors by registered trial count).

4 total trials 2 currently recruiting 1 completed early-phase tilt upper quartile by trial count

Zymeworks BC: 4 sponsored US clinical trials, 2 recruiting.

Zymeworks BC sponsors 4 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 1 completed. 0 of these trials are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Hepatocellular Carcinoma, with 1 trials.

Upper-quartile sponsor footprint

Zymeworks BC sits in the upper quartile of the sponsor corpus (#2,913 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

What is open in the Zymeworks BC pipeline

2 recruiting of 4 indexed (50% open); 1 completed (25%).

Phase mix: 0 late (III/IV) vs 4 early (I/II) (early-phase heavy).

Top condition: Hepatocellular Carcinoma (1 trial), 1 other listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Zymeworks BC: open-pipeline peers nationwide

Peers matched on 4 registered trials and 50% open enrollment, not the therapeutic-area sidebar.

Zymeworks BC sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 1.522.533.544.5 0%20%40%60%80% Total trials Recruiting share Zymeworks BC4D pharma60 Degrees PharmaceuticalsA2 BiotherapeuticsAbdul Latif Jameel Poverty Action Lab1200 Pharma1ST Biotherapeutics3ive Labs7 Hills Pharma
Zymeworks BC sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Zymeworks BC sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 4 trials (± recruiting share)

Sponsors near 50% open enrollment (± trial volume)

What to do with this Zymeworks BC page

4 registered trials is a research-attention snapshot, not an endorsement of Zymeworks BC or any single study.

  • 2 of Zymeworks BC's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Hepatocellular Carcinoma is the condition Zymeworks BC studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Hepatocellular Carcinoma trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Zymeworks BC pipeline card: 4 registered trials from official public datasets.Report a data error.